UY24717A1 - Nuevo tratamiento - Google Patents

Nuevo tratamiento

Info

Publication number
UY24717A1
UY24717A1 UY24717A UY24717A UY24717A1 UY 24717 A1 UY24717 A1 UY 24717A1 UY 24717 A UY24717 A UY 24717A UY 24717 A UY24717 A UY 24717A UY 24717 A1 UY24717 A1 UY 24717A1
Authority
UY
Uruguay
Prior art keywords
new treatment
treatment
huntingdon
tics
narcolepsy
Prior art date
Application number
UY24717A
Other languages
English (en)
Inventor
Dr John Morris Evans
Dr Andrew A Parsons
Dr Mervyn Thompson
Dr Neil Upton
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY24717A1 publication Critical patent/UY24717A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Derivados y análogos de benzopirano se describen como útiles para el tratamiento y/o la profilaxis de enfermedades degenerativas tales como corea de huntingdon, esquizofrenia, déficit neurológicos asociados con el sida, trastornos del sueno (incluidos trastornos del ritmo circadiano, insomnio y narcolepsia), tics,lesión traumática del cerebro, zumbido, y otras.
UY24717A 1996-09-18 1997-09-16 Nuevo tratamiento UY24717A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619492.3A GB9619492D0 (en) 1996-09-18 1996-09-18 Novel treatment

Publications (1)

Publication Number Publication Date
UY24717A1 true UY24717A1 (es) 2001-08-27

Family

ID=10800127

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24717A UY24717A1 (es) 1996-09-18 1997-09-16 Nuevo tratamiento

Country Status (30)

Country Link
EP (1) EP0939630B1 (es)
JP (1) JP2001500520A (es)
KR (1) KR20000036184A (es)
CN (1) CN1230885A (es)
AP (1) AP9901473A0 (es)
AR (1) AR008838A1 (es)
AT (1) ATE270102T1 (es)
AU (1) AU730465B2 (es)
BG (1) BG103252A (es)
BR (1) BR9712030A (es)
CA (1) CA2266681A1 (es)
DE (1) DE69729735T2 (es)
DZ (1) DZ2311A1 (es)
EA (1) EA199900306A1 (es)
ES (1) ES2223075T3 (es)
GB (1) GB9619492D0 (es)
HU (1) HUP9904638A3 (es)
ID (2) ID23175A (es)
IL (1) IL128786A0 (es)
MA (1) MA24321A1 (es)
NO (1) NO991292D0 (es)
NZ (1) NZ334271A (es)
OA (1) OA10998A (es)
PE (1) PE109898A1 (es)
PL (1) PL332313A1 (es)
SK (1) SK35199A3 (es)
TR (1) TR199900527T2 (es)
UY (1) UY24717A1 (es)
WO (1) WO1998011890A1 (es)
ZA (1) ZA978359B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
MX2010013313A (es) * 2008-06-05 2011-05-30 Minster Res Ltd Tratamientos novedosos.
WO2009147441A2 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
PT2464645T (pt) 2009-07-27 2017-10-11 Gilead Sciences Inc Compostos heterocíclicos fusionados como moduladores do canal de iões
EP2506846A1 (en) * 2009-12-03 2012-10-10 Proximagen Limited Treatment of allodynia and hyperalgesia
EP2506847A1 (en) * 2009-12-03 2012-10-10 Proximagen Limited Treatment of infectious diseases
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112721D0 (en) * 1991-06-13 1991-07-31 Smithkline Beecham Plc Novel treatment
US5510375A (en) * 1993-11-19 1996-04-23 Warner-Lambert Company Coumarin derivatives as protease inhibitors and antiviral agents
SG67930A1 (en) * 1994-06-10 1999-10-19 Smithkline Beecham Plc Benzopyrans and their use as therapeutic agents
GB9411635D0 (en) * 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
AU730465B2 (en) 2001-03-08
ES2223075T3 (es) 2005-02-16
KR20000036184A (ko) 2000-06-26
BR9712030A (pt) 1999-08-24
GB9619492D0 (en) 1996-10-30
IL128786A0 (en) 2000-01-31
OA10998A (en) 2003-03-04
HUP9904638A3 (en) 2001-08-28
NO991292L (no) 1999-03-17
PL332313A1 (en) 1999-08-30
EA199900306A1 (ru) 1999-08-26
NZ334271A (en) 2001-03-30
EP0939630A1 (en) 1999-09-08
AU4704797A (en) 1998-04-14
CA2266681A1 (en) 1998-03-26
JP2001500520A (ja) 2001-01-16
ATE270102T1 (de) 2004-07-15
AP9901473A0 (en) 1999-03-31
NO991292D0 (no) 1999-03-17
WO1998011890A1 (en) 1998-03-26
ID19542A (id) 1998-07-23
ZA978359B (en) 1999-03-17
MA24321A1 (fr) 1998-04-01
CN1230885A (zh) 1999-10-06
ID23175A (id) 2000-03-23
SK35199A3 (en) 2000-07-11
HUP9904638A2 (hu) 2001-05-28
DE69729735T2 (de) 2005-07-14
DZ2311A1 (fr) 2002-12-28
EP0939630B1 (en) 2004-06-30
PE109898A1 (es) 1999-03-21
AR008838A1 (es) 2000-02-23
BG103252A (en) 1999-09-30
TR199900527T2 (xx) 1999-06-21
DE69729735D1 (de) 2004-08-05

Similar Documents

Publication Publication Date Title
ATE209492T1 (de) Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
MX173791B (es) Procedimiento para la produccion de 2-metil-10(4-metil 1-piperazinil)-4h-tieno[2,3-b][1,5] benzodiazepina y producto obtenido
EP1133294A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, DAMAGE TO THE CENTRAL NERVOUS SYSTEM AND INFLAMMATORY DISEASES
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
UY24717A1 (es) Nuevo tratamiento
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
IL192078A0 (en) Recombinant ??-l-iduronidase,methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
IL193814A0 (en) 1 -acetyl- 3,3 dimethyl- 6- amino- 2, 3 - dihydroindole and process for producing same
DE60142236D1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
YU50800A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola
HK1080466A1 (zh) 用於治療過度增生疾病的稠合三環雜環
ATE90342T1 (de) 1-hydroxyvitamin d2-epimer und dessen derivate.
ATE213245T1 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
SG157231A1 (en) Substituted p-diaminobenzene derivatives
DE69738613D1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
WO2005081619A3 (en) Compounds and methods for increasing neurogenesis
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
MX9203409A (es) Proteinas bcrfi como inhibidores de la gama interferona.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
MY105555A (en) Heterocyclicguanidines as 5ht 3 antagonists.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20041027